NCT05059522 2026-04-14
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
Phase 3 Active not recruiting
Clinical Trials
53 trialsNCT05017012 2026-03-27
MK-3475A-C18
Merck Sharp & Dohme LLC
Phase 1 Active not recruiting
NCT05805501 2026-02-12
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04585815 2026-01-09
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Pfizer
Phase 1/2 Terminated
NCT06962787 2025-11-17
A Study of BL-B01D1+TKIĀ±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT04458259 2025-08-28
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT05949632 2025-08-03
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Terminated
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT04522323 2025-07-25
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
MedImmune LLC
Phase 1 Active not recruiting
NCT05256472 2025-03-06
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
Akeso
Phase 2 Active not recruiting
NCT05097599 2025-01-08
StrataPATH
Strata Oncology
Phase 2 Terminated
NCT00828919 2024-12-03
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
Pfizer
Phase NA Completed
NCT02639182 2024-11-18
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
Phase 2 Completed
NCT02667886 2024-10-03
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
X4 Pharmaceuticals
Phase 1/2 Completed
NCT05420220 2024-05-01
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Recruiting
NCT03472560 2024-04-09
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
Pfizer
Phase 2 Terminated
NCT04540705 2024-02-28
PIVOT IO 011
Bristol-Myers Squibb
Phase 1 Completed
NCT00920816 2022-05-06
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
Pfizer
Phase 3 Completed
NCT02493751 2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1 Completed
NCT02133742 2021-07-28
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Pfizer
Phase 1 Completed
NCT01806064 2020-10-19
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Terminated
NCT01999972 2020-09-24
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03289533 2020-09-04
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
Pfizer
Phase 1 Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT01599754 2019-09-20
ATLAS
SFJ Pharmaceuticals, Inc.
Phase 3 Terminated
NCT00569946 2019-06-05
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
Pfizer
Phase 2 Completed
NCT00219557 2019-05-14
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Pfizer
Phase 2 Completed
NCT00678392 2019-01-09
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Pfizer
Phase 3 Completed
NCT01210495 2019-01-09
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
Pfizer
Phase 2 Completed
NCT01441414 2019-01-08
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Pfizer
Phase 2 Terminated
NCT00835978 2017-05-30
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Pfizer
Phase 2 Completed
NCT00768755 2015-10-28
Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
Pfizer
Phase 1/2 Completed
NCT00460603 2013-12-06
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
Pfizer
Phase 1/2 Completed
NCT00842244 2013-11-27
Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer
Pfizer
Phase 1 Completed
NCT00389441 2013-11-25
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
Pfizer
Phase 2 Completed
NCT00600821 2013-11-08
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
Pfizer
Phase 2 Completed
NCT00615056 2013-04-19
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Pfizer
Phase 2 Completed
NCT00735904 2013-01-03
Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT00386555 2012-08-09
A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.
Arog Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT00282048 2012-07-31
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
Pfizer
Phase 2 Completed
NCT00471146 2012-07-16
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
Pfizer
Phase 3 Completed
NCT00076024 2012-06-26
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
Pfizer
Phase 1/2 Completed
NCT00094055 2012-06-26
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
Pfizer
Phase 2 Completed
NCT00094094 2012-06-26
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT00094107 2012-06-26
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Pfizer
Phase 2 Completed
NCT00071006 2012-06-08
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
Pfizer
Phase 2 Completed
NCT00447005 2012-05-23
Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00726752 2012-05-23
A Study In Patients With Advanced Solid Tumor
Pfizer
Phase 1 Completed
NCT00454649 2012-04-04
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Pfizer
Phase 1 Completed